Clinical Trials

Gallbladder Neoplasms, Cholangiocarcinoma

NCT04984837 2026-06-04

Study of Lacutamab in Peripheral T-cell Lymphoma

Phase 2 Not yet recruiting

49 enrolled

Lymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT07021989 2026-06-04

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

38 enrolled

Lymphoid

Hodgkin Disease

NCT07619313 2026-06-04

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

Phase 1 Not yet recruiting

46 enrolled

Pancreatic Neoplasms, Cholangiocarcinoma

NCT04753879 2026-06-03

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

38 enrolled

Pancreatic Neoplasms

NCT06770452 2026-06-03

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

133 enrolled

Pancreatic Neoplasms

NCT06632327 2026-06-02

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

1,100 enrolled

Thoracic

Lung Neoplasms

NCT07000084 2026-06-02

GAIN-BCG

330 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07144254 2026-06-02

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

Phase 1 Recruiting

24 enrolled

Sarcoma

Osteosarcoma

NCT04594772 2026-06-01

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

32 enrolled

Pancreatic Neoplasms

NCT07036380 2026-06-01

TACTIC

75 enrolled

Phase 4 Not yet recruiting

Advanced Biliary Tract Carcinoma

NCT07619235 2026-06-01

A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer

32 enrolled

Biliary Tract Neoplasms

NCT07529483 2026-05-29

ERASE-Chemo

35 enrolled

Phase 2/3 Not yet recruiting

Pancreatic Cystic Neoplasm

NCT07608224 2026-05-27

HOPE-07-MIBC

240 enrolled

Urinary Bladder Neoplasms

NCT06274879 2026-05-26

Ablatio

36 enrolled

Bile Duct Neoplasms

NCT05800587 2026-05-22

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

280 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT07325539 2026-05-22

LIGHT

55 enrolled

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT07603856 2026-05-22

REVIVE

39 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03093909 2026-05-20

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

Phase 1 Recruiting

44 enrolled

DermatologicGenitourinarySarcoma

Bone Neoplasms, Melanoma, Osteosarcoma, Urologic Neoplasms

NCT07598318 2026-05-20

Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations

Phase 2/3 Not yet recruiting

164 enrolled

Phase 2 Not yet recruiting

Cholangiocarcinoma

NCT07599995 2026-05-20

GENE

34 enrolled

Biliary Tract Neoplasms

NCT05615818 2026-05-19

SAFIR-ABC10

800 enrolled

Biliary Tract Neoplasms

NCT06904378 2026-05-19

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1/2 Recruiting

61 enrolled

Phase EARLY_PHASE1 Enrolling by invitation

Metastatic Pancreatic Ductal Adenocarcinoma

NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

18 enrolled

Phase 1/2 Active not recruiting

Muscle Invasive Bladder Urothelial Carcinoma

NCT00210041 2026-05-15

Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma

Phase 2 Completed

50 enrolled

Genital Neoplasms, Male

NCT03598595 2026-05-14

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

31 enrolled

Sarcoma

Osteosarcoma

NCT06591650 2026-05-14

GCND

GastrointestinalGenitourinary

33 enrolled

Gallbladder Cancer Unresectable

NCT07579195 2026-05-14

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

Phase 1/2 Not yet recruiting

12 enrolled

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT03017326 2026-05-13

PHITT

450 enrolled

Carcinoma, Hepatocellular, Hepatoblastoma

NCT01972919 2026-05-12

MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer

23 enrolled 8 charts

Pancreatic Neoplasms

NCT03415854 2026-05-12

NABPLAGEMD

Phase 2 Completed

34 enrolled 11 charts

Adenocarcinoma, Pancreatic Neoplasms

NCT05941741 2026-05-11

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

380 enrolled

Nasopharyngeal Carcinoma

NCT06323239 2026-05-11

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

148 enrolled

Nasopharyngeal Carcinoma

NCT06802835 2026-05-11

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Phase 1/2 Recruiting

148 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT06929286 2026-05-11

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

125 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07466238 2026-05-08

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Phase NA Recruiting

40 enrolled

Phase 2/3 Active not recruiting

Biliary Tract Neoplasms

NCT02135042 2026-05-07

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

685 enrolled

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT05415917 2026-05-07

Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy

Phase 2 Withdrawn

Pancreatic Neoplasms

NCT05524168 2026-05-07

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

41 enrolled

Nasopharyngeal Carcinoma

NCT03652428 2026-05-06

Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)

Phase 1/2 Recruiting

24 enrolled

Locally Advanced Pancreatic Cancer

NCT06023862 2026-05-06

DOVE

198 enrolled

Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT06822010 2026-05-06

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

28 enrolled

Urinary Bladder Neoplasms

NCT07569679 2026-05-06

Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer

124 enrolled

Biliary Tract Neoplasms

NCT07570849 2026-05-06

Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma

35 enrolled

Cholangiocarcinoma

NCT04807816 2026-05-05

TARSARC

Phase 2 Completed

58 enrolled

Sarcoma

Leiomyosarcoma, Neoplasm Metastasis, Sarcoma

NCT04481204 2026-05-04

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Phase 2 Withdrawn

Borderline Resectable Pancreatic Adenocarcinoma

NCT06015659 2026-05-04

ZN-c3 + Gemcitabine in Pancreatic Cancer

12 enrolled

Pancreatic Neoplasms

NCT06958328 2026-05-04

LAP100

356 enrolled

Pancreatic Neoplasms

NCT07097142 2026-05-04

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

486 enrolled

Urinary Bladder Neoplasms

NCT07030140 2026-05-01

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

38 enrolled